New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
04:55 EDTALKS, ALKS, ANGO, ANGO, SNSS, SNSS, VHS, VHS, IART, IART, OCR, OCR, BKD, BKD, BAX, BAX, ARIA, ARIARBC Capital to host a conference
Healthcare Conference is being held in New York on February 26-27.
News For ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
06:36 EDTBAXKamada announces second extension of strategic agreement with Baxter
Kamada (KMDA) announced the second extension to supply Glassia to Baxter (BAX) in its strategic agreement with the biopharmaceutical business of Baxter. Through the extended agreement, Kamada secured $26M in additional revenues of Glassia, the company’s proprietary, ready-to-infuse liquid alpha-1 antitrypsin treatment that is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency, through 2017. As a result, Kamada expects that total revenue generated through this agreement from October 2010 through end of 2017 will increase to a minimum of $191M compared with a minimum of $110M contained in the original agreement executed in 2010 and a minimum of $165M contained in the May 2013 extension. In addition, the company reports that the supply of Glassia to Baxter has been extended through 2017 and that the transition to royalty payments for Glassia produced by Baxter is not expected to begin before 2018. Until that time, Kamada will continue to produce Glassia for distribution by Baxter. Kamada is confident in its ability to support the increased demand from Baxter throughout the term of the amended agreement.
06:06 EDTSNSSStocks with implied volatility above IV index mean; SNSS AMD
Subscribe for More Information
September 26, 2014
06:07 EDTSNSSStocks with implied volatility above IV index mean; SNSS ADHD
Stocks with implied volatility above IV index mean; Sunesis (SNSS) 329, Alcobra (ADHD) 334 according to iVolatility.
05:40 EDTBAXPharmaEngine, Merrimack Pharmaceuticals amend MM-398 license agreement
Subscribe for More Information
September 25, 2014
13:39 EDTSNSSSunesis volatility elevated into data from trial
Sunesis overall option implied volatility of 241 is above its 26-week average of 157 according to Track Data, suggesting large price movement ahead of the upcoming release of data from a trial of its Qinprezo drug that is expected in the coming weeks.
September 24, 2014
09:52 EDTALKSAlkermes expects to receive $59M in connection to Acorda-Civitas deal
Subscribe for More Information
09:05 EDTBAXOn The Fly: Pre-market Movers
Subscribe for More Information
07:39 EDTBAXMerrimack to hold a conference call
Conference call to discuss the exclusive license and collaboration agreement with Baxter International for the development and commercialization of MM-398 also known as "nal-IRI" will be held on September 24 at 8:30 am. Webcast Link
07:06 EDTBAXBaxter, Merrimack enter exclusive ex-U.S. licensing deal for MM-398
Subscribe for More Information
September 22, 2014
13:51 EDTSNSSSunesis volatility elevated into data from trial
Sunesis overall option implied volatility of 298 is above its 26-week average of 156 according to Track Data, suggesting large price movement ahead of the upcoming release of data from a trial of its Qinprezo drug that is expected in the coming weeks.
09:41 EDTSNSSCitadel Advisors reports 5.3% passive stake in Sunesis
Subscribe for More Information
07:08 EDTOCROmnicare appoints Ashok Singh as Chief Information Officer
Omnicare announced Ashok Singh has been appointed senior vice president, Chief Information Officer effective October 1. Most recently, Singh served as senior vice president, Information Technology for TransUnion Healthcare.
September 18, 2014
17:57 EDTARIAARIAD CEO buys 25K shares of company stock
Subscribe for More Information
08:38 EDTIARTIntegra LifeSciences announces commercial release of Integra Freedom system
Subscribe for More Information
September 17, 2014
11:26 EDTIARTIntegra LifeSciences management to meet with Oppenheimer
Subscribe for More Information
08:44 EDTBAXJPMorgan biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:43 EDTBKDBofA/Merrill to hold a conference
Subscribe for More Information
07:27 EDTIARTIntegra LifeSciences price target raised to $68 from $59 at Piper Jaffray
Piper Jaffray raised its price target for shares of Integra LifeSciences to $68 saying meetings with the company's CEO increased its confidence in its Overweight rating. Piper thinks Integra's performance will improve in 2015 and expects the stock to significantly outperform over the next 12 months.
06:09 EDTIARTIntegra LifeSciences to acquire Medtronic instrumentation lines for $60M
Integra LifeSciences (IART) and Medtronic (MDT) announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60M in cash. Integra expects the transaction to close in Q4. Integra will acquire a portfolio of approximately 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments, as well as the St. Aubin le Monial, France manufacturing facility. Sales from the products being acquired totaled approximately $30M, two-thirds of which were generated outside the U.S. Integra expects to record approximately $27M-$30M in revenue and approximately 10c of adjusted EPS in calendar 2015 from this acquisition. The earnings accretion should rise after the first year once certain sales transitions are complete. The company expects the acquisition to contribute less than $5M in revenue and be neutral to earnings in Q4. The transition and integration is expected to be completed by 2H15.
September 16, 2014
13:42 EDTSNSSSunesis volatility elevated into data from trial
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use